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How transplantation came to be a clinical discipline can be pieced together by perusing two volumes of 
reminiscences collected by Paul I. Terasaki in 1991-
1992 from many of the persons who were directly involved. 
One volume was devoted to the discovery of the major histo-
compatibility complex (MHCI, with particular reference to 
the human leukocyte antigens (BLAs) that are widely used 
today for tissue matching. I The other focused on milestones 
in the development of clinical transplantation.2 All the con-
tributions described in both volumes can be traced back in 
one way or other to the demonstration in the mid-1940s by 
Peter Brian Medawar that the rejection of allografts is an 
immunological phenomenonY 
Ten years later (1953), Billingham, Brent, and MedawarS 
showed that tolerance to skin allografts could be induced by 
inoculating fetal or prenatal mice with immunocompetent 
spleen cells from adult donors. Because of their immunologi-
cal immaturity, the recipients were incapable of rejecting the 
spleen cells with progeny that survived indefinitely. Specific 
nonresponsiveness to donor strain tissues was retained as the 
reCipient animals grew to adult life, while normal reactivity 
evolved to third-party grafts and other kinds of antigens. 
This was not the first demonstration that tolerance could 
be deliberately produced. Analogous to the neonatal trans-
plant model, Traub6 showed in 1936 that the lymphocytic 
~horiomeningitis virus (LCMV) persisted after transplacental 
infection of the embryo from the mother or by injection into 
neWborn mice. However, when the mice were infected as 
a~ultsI the virus was eliminated immunologically. Similar 
~ servations had been made in experimental tumor models. 
urphy7 reported in 1912 on the outgrowth of Rous chicken 
s~coma cells on the chorioallantoic membranes of duck or 
~ton egg embryos, which could be reversed by inoculation 
tioad~lt chicken lymphoid cells,S whereas sarcoma implanta-
n lllto adults was not possible. 
th The observations of Murphy and Traub did not influence 
an~earl: development of transplantation. Instead, the impetus 
hi ratIonale for the experiments of Billingham, Brent, and 
edawary and similar studies in chickens by Hasek/o orig-
Allograft Acceptance Versus Acquired Tolerance ...... 1693 
Conclusion ..................................... 1697 
Epilogue ........................................ 1697 
References ...................................... 1697 
inated with Owen,ll who demonstrated that freemartin cattle 
[the calf equivalent of human fraternal [dizygotic] twins) 
became permanent hematopoietic chimeras if fusion of their 
placentas existed in utero, allowing fetal cross-circulation 
[Fig. 79.1); such animals permanently accept each other's 
skin.12 Burnet and Fenner13 predicted that this natural chime-
rism and tolerance to other donor tissues and organs could be 
induced by the kind of experiments successfully performed 
by Billingham, Brent, and Medawar. However, Billingham and 
Brent14,lS soon learned that, in mice, parallel with similar 
observations by Simonsen16 in chickens, the penalty for infu-
sion of immunocompetent hematopoietic cells was graft-
versus-host disease [GVHD) unless there was a close genetic 
relationship (i.e., histocompatibility) between the donor and 
recipient. 
This discovery was the beginning of modem transplanta-
tion immunology, an extensive history of which has been 
written by Brent,17 one of its principal architects. Each cell-
and organ-defined branch of transplantation also has had 
its historians, who have described the stages through which 
specific kinds of procedures moved to the bedside from 
experimental laboratories or in some cases directly. The 
culminating clinical events can be capsulized with a list of 
the first successful allotransplantation, in humans, of the 
kidney/8liver/9 heart/o,21 lung,22 pancreas,23 intestine,24 mul-
tiple abdominal viscera,25 and bone marrow.26-29 
Although such mil.estones and dozens of lesser ones are 
important, the emphasis in this account is on developments 
that were applicable to all varieties of allografts and respon-
sible for major transitions in transplantation ideology. It will 
become apparent as the layers of history are peeled away that 
there were only two seminal tuming points in the evolution 
of clinical transplantation. One was the induction of chime-
rism-associated neonatal tolerance by Billingham, Brent, and 
Medawar in 1953. The second was the demonstration in 
1962-1963 that organ allografts could self-induce tolerance 
with the aid of irnmunosuppression.30 All subsequent devel-
opments in organ transplantation depended on exploitation 
of this principle, using variations of the drug strategy that had 
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FIGURE 79.1. The chimerism in freemartin (fraternal twins) 
described by Owen.ll Cross-tolerance to formed blood elements fol-
lowed intrauterine circulatory exchange in dizygotic twins. Mutual 
tolerance to skin grafts was later proved by Anderson with Medawar 
et al. 12 (From Starzl and Butz,l46 by permission of Surgical Clinics of 
North America.) 
made its discovery possible. Ironically, the downside of the 
resulting revolution in organ transplantation was the early 
introduction of a conceptual error that distorted the matura-
tion of transplantation immunology and adversely affected 
the orderly development of general immunology. 
The error, which was not corrected until well into the 
1990s,31-33 was the conclusion by consensus that organ 
allograft acceptance involved different mechanisms compared 
to the chimerism-dependent ones of neonatal tolerance and 
its clinical analogue of bone marrow transplantation. Conse-
quently, the vast literature that sprang up in the intervening 
30 years admirably documented the progression of improve-
ments in clinical transplantation while failing to explain 
what was being accomplished.34 Therefore, the reader may 
profit by skipping to the last section of this chapter (1/ Allograft 
Acceptance Versus Acquired Tolerance") before attempting 
to understand what went on between 1963 and 1993 and 
before. 
Prehistory: Before Immunosuppression 
An indelible mark on the pages of transplantation history was 
left with the perfection of techniques for organ revasculariza-
tion by surgical anastomosis in the laboratories of Alexis 
Carrel at the beginning of the 20th century.3S Aside from the 
technical contributions, which also provided the foundation 
for conventional vascular surgery, Carrel recognized that 
transplanted organ allografts were not permanently accepted, 
although he did not know why. 
Using vascular surgical techniques, animal research in 
transplantation was most highly focused on the kidney for 
most of the next half-century.36-38 The extrarenal vacuum 
rapidly was filled between 1958 and 1960 with the develop-
ment in several laboratories of canine models with which to 
study all the intra-abdominaP9-43 and thoracic organs.44-40 
Although each organ presented specific technical and physi-
ological issues, the core problems of immunosuppression 
tissue matching, and allograft preservation eventually wer~ 
worked out mainly with the kidney and liver and applied to 
other organs with minor modifications. 
Hetero- (Xeno-)transplantation 
The first known attempts at clinical renal transplantation by 
vascular anastomoses were made between the beginning of 
the 19th century and 1923 in France/7 Gerrnany,48 and else. 
where (summarized by Groth49) using pig, sheep, goat, and 
subhuman primate donors. None of the kidneys functioned 
for long, if at all, and the human recipients died a few hours 
to 9 days later. No further animal-to-human transplantations 
were tried again until 1963, after immunosuppression was 
available.5o,51 
Homo- (Ailo-Jtransplantation 
In 1936, Voronoy of Kiev, Russia, reported the transplantation 
of a kidney from a cadaver donor of B blood type to a recip-
ient of 0 blood type,s2 in violation of what have become 
accepted rules of tissue transfe~PIR4 (Table 79.1). In addition, 
the allograft was jeopardized by the residual risk of acute 
mercury poisoning (from a suicide attempt) that caused the 
recipient's renal failure. A final adverse factor was the 6-h 
lapse between the donor's death and organ procurement. The 
allograft did not make any urine during the 48 h of the 
patient's posttransplant survival. Although other attempts 
may have been made by VoronoY,S5 another 15 years passed 
before significant kidney transplant activities were resumed 
in France. 
In 1951, Rene KUSS56 and Charles Dubost57 in Paris and 
Marceau Servelle in Creteil58 carried out a series of renal 
transplantations with kidneys removed from convict donors 
immediately after their execution by guillotine. The next 
year, the French nephrologist Jean Hamburger, in collabora-
tion with the urolOgist Louis Michon at the H6pital Necker 
in Paris, reported the mother-to-son transplantation of a 
kidney that functioned well for 3 weeks before rejection. 59 
The procedure developed by Kuss and the other French sur-
TABLE 79.1. Direction of Acceptable Organ Transfer When the 
Donor and Recipient Have Different ABO Red Cell Types. 
o to non-O 
Rh-to Rh+ 
Rh+ to Rh-
A to non-A 
B to non-B 
AB to non-AB 
Safe 
Safe 
Relatively safe 
Dangerous 
Dangerous 
Dangerous 
For organ transplantation, 0 is universal donor. and AB is universal recipient. 
With the transplantation of bone marrow allografts or of lymphoid· rich organ 
allografts le.g., intestine or liver), enough antihost isoagglutinins may be pro· 
duced by the allograft to cause serious or lethal hemolysis in a significant 
number of cases (humoral GVHD).54 Consequently, the rules summarized ill 
this table are fully applicable only with leukocyte-poor organs such as the 
kidney and heart [see the section, "Allograft Acceptance Versus AcqUlred 
Tolerance"). 
Source: From StarzlI1964j.S3 
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eons and used for this first live donor kidney transplantation ~as been performed hundreds of thousands of times since 
then. The operation's relative freedom from chroruc morbId-
ity would soon be demonstrated with the identical (monozy-
gotic) twin transplantations of Joseph E. Murray and John 
Merrill and their associates60 at the Peter Bent Bngham Hos-
pital in Boston. 
The efforts by the French teams were widely known, and 
visitors flocked to .Paris in the early 1950s to learn firsthand 
from the experience. One of the observers of the extraperito-
neal pelvic operation (often called the Kuss procedure in 
Europe) was John Merrill, as Hume, Merrill, et al. 61 described 
in their account of the first clinical trials at the Peter Bent 
Brigham Hospital. In Hume's nine Boston cases, however, all 
but one of the allografts were placed in the recipient thigh, 
revascularized from the femoral vessels, and provided with 
urinary drainage by skin ureterostomies. 
The exceptional case in the Boston series61 was the first 
one. The donor and recipient operations were performed in 
Springfield, Massachusetts, on March 30, 1951, by Dr. L.H. 
Doolittle. The donor kidney was excised because of a carci-
noma of the lower ureter and implanted in the vacated renal 
fossa of the recipient after removal of the native organ. The 
recipient patient had been under short-term dialysis care at 
the Brigham, where the first artificial kidney in the United 
States had been brought from Holland by Wilhelm Kolff 
and modified by Harvard engineers, as described in detail by 
Moore. 62 
The next eight operations, in which the allografts were 
placed in the anterior thigh location, were performed by 
Hume in Boston between April 23, 1951, and December 3, 
1952. The report of the nine cases stands as one of the medical 
classics of the 20th century, providing an extensive clinical 
and pathological profile of renal allograft rejection in untreated 
human recipients. The descriptions complemented the report 
of Michon and Hamburger of the live donor French case (see 
earliet9) and the path£nding studies in dogs by the Dane, 
Morten Simonsen/7 and W. James Dempster in England.38 It 
is noteworthy that Hume treated some of his patients with 
adrenocortical steroids. It was already known from experi-
mental studies that steroid therapy modestly mitigated 
Primary skin graft rejection63-65 and even slowed the acceler-
ated rejection of presensitized recipients.66 
Although compilation of the Boston series postdated the 
early French efforts (as generously annotated by Hume), the 
commitment of the Harvard group to transplantation was 
eVident long before the availability of effective immunosup-
pression. Burne, who moved in 1956 from Boston to the 
Medical College of Virginia (Richmond), remained a major 
force in transplantation until his death in the crash of a 
private plane (of which he was the pilot) near Los Angeles in 
May 1973. His friend and colleague, John Merrill, who 
7emained in Boston, drowned off the beach of a Caribbean 
lsland in 1984. 
None of the European and American efforts to this time, 
Or all together, would have had any lasting impact on medical 
:actice were it not for what lay ahead. The principal ingre-
ents of organ transplantation-immunosuppression, tissue 
~tChingI and organ procurement (and preservation)-were 
S} 1 ~nknown or undeveloped. The only unequivocal example 
o clinically significant allograft function through 1954 was 
prOVided by one of the nonimmunosuppressed patients of 
Hume et al.,61 whose thigh kidney produced life-supporting 
urine output for 5 months. Similar claims about function of 
an allograft transplanted to the orthotopiC 10cation67 (i.e., as 
in Doolittle's case61 ) or to a nonanatomical site68 were con· 
sidered implausible by later critics. 
The existence of these cases was public knowledge, but 
the failure of all the grafts (usually with death of the patients) 
left very little room for optimism. The perception, if not the 
reality, of hopelessness was changed at the Peter Bent Brigham 
Hospital 2 days before Christmas in 1954, when a kidney was 
removed from a healthy man by the urologist J. Hartwell Har-
rison and transplanted by Joseph E. Murray to the pelvic 
location of the donor's uremic identical twin brother.6o,69 
Although no effort was made to preserve the isograft, it func-
tioned promptly despite 82min of warm ischemia. The recip-
ient lived for nearly 25 years before dying of atherosclerotic 
coronary artery disease. 
According to Merrill et a1.,60 exploitation of genetic 
identity for whole-organ transplantation had been suggested 
by the recipient's physician, David C. Miller, at the Public 
Health Service Hospital, Boston. It already was well known 
that identical twins did not r~ject each other's skin grafts.70 
To ensure identity, reciprocal skin grafting was performed in 
the Boston twins. Although the identical twin cases attracted 
worldwide attention, organ transplantation now had reached 
a dead end. Further progress in the presence of an immuno-
logical barrier would require effective immunosuppression. 
The possibility of meeting this objective could only be 
regarded as bleak. To understand why, it is necessary to appre-
ciate not only how barren the landscape of immunology was, 
but also how slowly the preexisting information had been 
filled in. 
A century had passed between the first vaccination pro-
cedure in 1796 (Edward Jenner, smallpox) and the confirma-
tion of the immunization prinCiple by Louis Pasteur (with 
chicken cholera and rabies). The proof obtained by Robert 
Koch that microorganisms caused anthrax (1876) and subse-
quently many other infectious diseases stimulated a search 
for the host-protective mechanisms. This search yielded com-
ponents of the immune response: antibodies (Emil Adolf von 
Behring and Shibasaburo Kitasato, 1890); immune cells (liya 
Metchnikoff, 1884); and complement (Jules Bordet, 1895). In 
addition, Paul Erlich developed the side-chain theory (1890), 
according to which each cell has a vital center of protein 
substance and a series of side chains (later known as recep-
tors) to which toxic substances as well as nutrients were 
absorbed and then assimilated. In 1910, Erlich introduced the 
first antimicrobial drug, an arseni<:al compound effective 
against syphilis, yaws, and several other infections. 
Decades passed between the cluster of great contributions 
at the tum of the 20th century and the proposal by F. McFar-
lane Burnet that antibodies were produced in each individual 
only to those antigens to which he or she was exposed. 13 The 
lack of major movement between times is evident from a list 
of Nobel Prizes (Table 79.2). Although 6 of the first 17 Nobel 
laureates (1901-1919) were honored for work relevant to 
immunology/transplantation, there was only one further 
example (Karl Landsteiner, ABO blood groups) among the 
next 57 [1920-1959). Beginning with Burnet and Medawar, 17 
of the 77 laureates since 1960 have been directly responsible 
for, contributed to, or directly benefited from advances in 
transplantation (Table 79.2). 
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TABLE 79.2. Nobel Prizes Related to Immunology/ 
Transplantation. 
Year Name Accomplishment 
1901 Emil Adolf von Behring Discovery of antibodies 
1905 Heinrich Hermann Robert Cause and effect of 
Koch microorganisms and 
infection 
1908 Paul Ehrlich Side-chain Ireceptor) concept; 
champion of humoral 
immunity; antimicrobial 
therapy 
Ilya Metchnikoff Champion of cellular 
immunity 
1912 Alexis Carrel Vascular surgery and 
transplantation 
1919 Jules Bordet Discovery of complement 
1930 Karl Landsteiner Discovered ABO blood group 
antigens 
1960 Sir Frank MacFarlane Clonal selection hypothesis 
Burnet 
Sir Peter Brian Medawar Acquired transplantation 
tolerance 
1972 Gerald M. Edelman Characterized 
immunoglobulins 
Rodney R. Porter Clarified structure of antibody 
molecule 
1980 Baruj Benacerrat Discovered immune response 
genes and collaborated in 
discovery of MHC 
restriction 
rean Dausset Discovered first HLA antigen 
George Davis Snell Discovery of major 
histocompatibility complex 
IMHC) gene in mice 
1984 Niels .Raj Jerne Important immunological 
hypotheses 
Georges J.F. Kohler Hybridoma technology 
Cesar Milstein Hybridoma technology 
1985 Michael Stuart Brown Hepatic control of cholesterol 
metabolism lwith 
Goldstein)' 
Joseph Leonard Goldstein 
1987 Susumu Tonegawa Discovered somatic 
recombination of 
immunological receptor 
genes 
1988 Gertrude Belle Elion Codiscovery lwith Hitchings) 
of 6-mercaptopurine 16-MP) 
and azathioprine 
George Herbert Hitchings 
1990 Joseph E. Murray Kidney transplantation 
E. Donnall Thomas Bone marrow transplantation 
1996 Rolf Zinkemagel Codiscovered lwith Doherty) 
the role of MHC in 
adaptive immune response 
to pathogens 
Peter C. Doherty 
'Proved with liver transplantation for indication of hypercholesterolemia.249.:ZSo 
In Burnet's original hypothesis of immunity, antibody 
synthesis was postulated to occur after an antigen locked on 
to a membrane-bound receptor (a version of the antibody) that 
was displayed at the surface of an immune cell. After binding 
the antibody, the cell proliferated, producing a clone that 
secreted identical antibodies (the clonal selection theory). 
Nossal subsequently proved that the clone rose from a single 
cell ("one cell/one antibody").71 Although Burnet's hypothesiS 
was not yet complete, it was to become the cornerstone of 
modem. immunology. 
The Concept of Immunosuppression 
With Recipient Cytoablation 
The transition of tissue and organ transplantation from an 
exercise in futility to tenuous practicality involved a surpris-
ingly small number of advances that were interspersed with 
long periods of frustration. After Medawar's demonstration in 
1944 that rejection was an immunological event/,4 a logical 
and inevitable question was, why not protect the organ 
allograft by weakening the immune system? This idea was 
tested in rabbits in 1950-1951 with cortisone63,64 and total-
body irradiation (TBI).72 Both prolonged skin graft survival for 
only a few days. 
Neither these results nor those reported with cortisone in 
1952 by Cannon and Longmire65 in a chicken skin graft model, 
generated much optimism. However, the Cannon-Longmire 
report contained three observations that, in retrospect, pre-
saged not only the acquired neonatal tolerance produced by 
Billingham, Brent, and Medawar the following year, but also 
the most important clinical advances in transplantation of 
the succeeding decades. First, skin grafts exchanged between 
I-day-old chicks of different breeds had a high rate of initial 
engraftment and a 6% incidence of pennanent take. Second, 
the window of neonatal opportunity was gone by 4 days. 
Third, and most important, the percentage of pennanent 
engraftment of neonatally transplanted skin was increased to 
more than 20% by a course of cortisone with no increase of 
mortality. 
The significance of the third observation was recognized 
by Cannon and Longmire, who wrote: 
Although the cortisone did not entirely prevent a reaction in the 
homograft, it did decrease the incidence of reaction. Even more 
important, the increased incidence of reaction [sic] free grafts 
appeared to maintain itself after the drug was discontinued_ This 
phenomenon is one which up to the present time has not been found 
in homograft experiments on mammals and humans. 
Despite a 1957 confi.rmatory follow-up study/3 the neglected 
Cannon-Longmire article faded quickly from the collective 
memory of both basic scientists and clinicians. In contrast, 
the 1953 achievement of acquired neonatal tolerance by Bill-
ingham, Brent, and Medaw:u-5,9 ignited interest in transplanta-
tion as never before. Two years later, Main and Prehn74 
attempted to simulate in adult mice the environment that 
allowed the acquisition of neonatal tolerance. The three steps 
were first to cripple the immune system with supralethal TBI; 
next to replace it with allogeneic bone marrow (producing a 
hematolymphopoietic chimera); and finally to engraft skin 
from the same inbred strain as the donor of the bone 
marrow. 
The experiments were successful/4 but as in the neonatal 
tolerance model, lethal GVHD could be avoided only when 
there were "weak" histocompatibility barriers. 75 Applying the 
chimerism strategy for kidney transplantation in beagle dogs 
in Cooperstown, New York, Mannick et aF6 reported good 
renal allograft function in a supralethally irradiated recipient 
that also was given donor bone marrow and was a hemato-
'* I 
'4 
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lymphopoietic chimerai the animal lived for 73 days before 
dying of pneumonia. Because it was demonstrated later that 
this kind of outcome depended on the identity of the dog 
lymphocyte antigens (DLAs),77.7s an accidental DLA match 
was suspected in retrospect to have been present in Mannick's 
experiment. Efforts by Hume et al. 79 and subsequently by 
Rapaport and coworkers80 and others to broaden the range of 
acceptable histoincompatibility inevitably led to lethal 
eVHD, rejection, or both. 
BONE MARROW TRANSPLANTATION 
With the impasse, workers in bone marrow and whole-organ 
transplantation took separate pathways. Bone marrow trans-
plantation was dependent a priori on the classic chimerism-
associated acquired tolerance induction defined at the outset 
by Billingham, Brent, and Medawar in the neonatal model. In 
spite of the fact that only highly histocompatible donors 
could be used, clinical success with bone marrow engraft-
ment was achieved in 1963 by Mathe et al. in Paris,26 whose 
patient lived for 2 years with chronic GVHD before commit-
ting suicide. 
Five years later, Gatti et al. in Minneapolis28 and Bach et 
al. at the University of Wisconsin27 each transplanted bone 
marrow to recipients who are well today. The lifetime efforts 
of Thomas/9 van Bekkum,BI and others fueled the maturation 
of bone marrow transplantation into accepted clinical therapy 
for numerous hematological diseases (including malignan-
cies), acquired immunodeficiency disorders, mesenchymal-
based inborn errors of metabolism, and an assortment of other 
indications. 
Bone marrow transplantation was an intellectual triumph. 
Its development could be traced in a straight line back to 
the experiments of Main and Prehn74 and before that to the 
acquired neonatal tolerance of Billingham, Brent, and 
Medawar"·9 and the natural tolerance of Owens' freemartirl 
cattle. II 
WHOLE-ORGAN TRANSPLANTATION 
In contrast, clinical organ transplantation, which preceded 
bone marrow transplantation by a decade, appeared to be 
disconnected from a rational base when it was concluded that 
organ engraftment seemingly was independent of chimerism. 
An extension of the Main-Prehn strategy (i.e., lethal TBI fol-
lowed by bone marrow and kidney allografts as in Mannick's 
dog) was used by Murray et al,82 in only two cases, both in 
1958. The next 10 kidney recipients in Boston were condi-
tioned with sublethal TBI without bone marrow.1B.B2.B3 Of the 
12 irradiated patients, 11 died after 0 to 28 days. 
The survivor (who was not given bone marrow) had ade-
quate renal function from the time his fraternal twin brother's 
kidney was transplanted on January 24, 1959, until he died in 
July 1979 (Table 79.3)_ With this historical accomplishment, 
the genetic barrier to organ transplantation had been defini-
tively breached for the first time in any species. 18 Five months 
later, Hamburger et al.B4 added a second fraternal twin trans-
plantation using the same treatment (Table 79.3). This second 
recipient had good renal function until his death 26 years later 
from carcinoma of the urinary bladder. 
In these two dizygotic twin cases, it was conceivable that 
the donor and recipient placentas had fused during gestation, 
analogous to Owen's freemartin cattle (see Fig. 79.1). This 
suspicion was put to rest at the Paris centers of Jean Ham-
burger8s and Rene KUSSB6 by four more examples during 1960-
1962 of survival of 1 year or more. In Kuss' two cases, the 
donors were not related (see Table 79.3). During the critical 
period from January 1959 through the spring of 1962, the 
cumulative French experience was the principal (and perhaps 
the only) justification to continue clinical trials in kidney 
transplantation. 
The experience from Boston and Paris summarized in 
Table 79.3 showed that bone marrow infusion was not a 
necessary condition for prolonged survival of kidney allografts 
and ostensibly eliminated the requirement of chimerism. The 
stage was set for drug therapy. In fact, both Hamburger and 
Kuss mentioned the use of adrenal cortical steroids as an 
adjunct to TBI (Table 79.3), but neither the dose nor the indi-
cation for the steroids was described. In addition, KUSS86 sec-
ondarily administered 6-mercaptopurine (6-MP) to one of his 
cytoablated patients as early as August 1960 "on the basis of 
the recent results of the experimental studies conducted by 
Calne"s7 (see next section). Calne had made an invited visit 
to the Paris center a few months earlier (Rene Kuss and Roy 
Calne, personal communication). 
~ TABLE 79.3., " 5; Kidney Transplantation with 6, Months or More Survival as of March 1963. 
Case City References Date Donor Survival (months? 
Boston lSi 82, 83 January 24, 1959 Frat=al twin >50 
2 Paris 84,85 June 29,1959 Fraternal twin >5 
3 Paris 86 June 22, 1960 UnrelatedC 18 (died) 
4 Paris 85 December 19, 1960 Mother 12 (died) 
5 Paris 86 March 12, 1961 UnrelatedC 18 (died) 
6 Paris 18 February 12,1962 Cousinc >13 
7 Boston 83, lOS April S, 1962 Unrelated 10 
'Boston: J.E. Murray (patients 1, 7); Paris: J. Hamburger (patients 2, 4, 6); R. Kuss (patients 3, 5). 
b<fhe kidneys in patients I, 2, and 6 functioned for 20;5, 25, and 15 years, respectively. Patient 7 rejected 
his graft after 17 months and died after return to ,dialysis. 
"Adjunct steroid therapy. 
• 
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Some authorities have considered irradiation-induced and 
drug-induced graft acceptance to be different phenomena.49,83,88 
More recently, it has become obvious that the variable degree 
of graft acceptance achieved with sublethal TBI between 
January 1959 and February 1962 was fundamentally the same 
as that seen in tens of thousands of drug-treated humans 
following transplantation of various whole organs (see the 
section" Allograft Acceptance Versus Acquired Tolerance"). 
With Drug Immunosuppression 
After it was learned that TBI alone could result in prolonga-
tion of kidney allografts, it was logical to focus the search for 
immunosuppressive drugs on myelotoxic agents that mim-
icked irradiation. In September 1960, Willard Goodwin of Los 
Angeles produced severe bone marrow depression with meth-
otrexate and cyclophosphamide in a young female recipient 
of her mother's kidney. The patient subsequently developed 
several rejections that were associated with bone marrow 
recovery. They were temporarily reversed with prednisone 
several times during the 143 days of survival. It was the Brst 
example of protracted human kidney allograft function with 
drug treatment alone.89 However, the case was not reported 
until 1963. 
Kidney transplant surgeons were quick to realize that 
bone marrow depression should be avoided, not deliberately 
imposed, following the demonstration by Schwartz and 
Dameshek90 that 6-mercaptopurine (6-MP) in a nontransplant 
rabbit model was immunosuppressive in sub myelotoxic 
doses. Within a few months after their seminal discovery, 
Schwartz and Dameshek91 and Meeker2 (working with 
Condie, Weiner, Varco, and Good) showed that 6-MP caused 
a dose-related delay of skin graft rejection in rabbits. Aware 
of these results but independent of each other, Calne93 in 
London and Zukoski, Lee, and Hume94 in Richmond, Virginia, 
demonstrated the same thing in the canine kidney transplant 
model. In June 1960, CaIne moved from the Royal Free Hos-
pital to join Murray at the Peter Bent Brigham Hospital in 
Boston in further preclinical studies of 6-MP and its analogue, 
azathioprine.83,95-97 
The two drugs had been developed originally by Gertrude 
Elion and George Hitchings as antileukernia agents.98 Their 
possible use in transplantation was greeted at Brst with fever-
ish enthusiasm because it was generally conceded that recip-
ient cytoablation would permit success in only occasional 
cases of human renal transplantation. Although approxi-
mately 95 % of the mongrel canine kidney recipients treated 
with 6-MP or azathioprine died in fewer than 100 days from 
either rejection or infection, occasional examples were 
recorded of long-term or seemingly permanent allograft accep-
tance99- 102 following discontinuance of a 4- to 12-month course 
of immunosuppression. The number of these animals was 
discouragingly small, but it was an accomplishment never 
remotely approached using TBI, with or without adjunct bone 
marrow. Survival of Mannick's single cytoablated animal for 
73 days after combined bone marrow and kidney transplanta-
tion had been the previous high-water mark in dogs (see 
earlier76 ). 
The survival of some of CaIne's animals beyond 6 months 
led to the decision at the Brigham to begin clinical trials with 
chemical immunosuppression. However, the poor therapeu-
tic margin of 6-MP and azathioprine when used alone in dogs 
was recognized. CaIne and Murray also were forewarned by 
an earlier clinical experience of Hopewell, Calne, and BeSWick 
et aL,I03 which was not published until 1964, in which 6-MP 
had been used to treat three kidney recipients (including 
one with a live donor) in 1959-1960; all three recipients 
had died. 
Consequently, the canine studies of 6-MP and azathio-
prine in Boston were highly focused on finding more effective 
drug combinations.83,9s,97,J04 Although adrenocortical steroids 
were tested, they did not appear to potentiate the value of 
azathioprine/s,97 prompting Murray in his clinical trial to opt 
for adjunct cytotoxic agents such as azaserine and actinomy-
cin c.83 Only 1 of the first 10 kidney recipients treated with 
either 6-MP (n = 2) or azathioprine-based immunosuppression 
(n = 8) survived for more than 6 months (see the last entry in 
Table 79.3).83,105 
At the nadir of the resulting pessimism, two reproducible 
observations, Brst in dogs and then in humans, were made at 
the University of Colorado. Taken together, these events pro-
foundly shaped future developments in transplantation of 
all organs and eventually of bone marrow. The observations 
were encapsulated in the title of a report published in 
October 1963: "The Reversal of Rejection in Human Renal 
Homografts With the Subsequent Development of Homograft 
Tolerance. ,,30 
The reversal was readily accomplished by temporarily 
adding unprecedented high doses of prednisone (200mg/ 
day) to baseline immunosuppression with azathioprine. The 
evidence that the live donor kidneys had self-induced toler-
ance under an umbrella of immunosuppression was equally 
clear. Most of the recipients had a subsequent progressively 
diminishing need for immunosuppression, usually to doses 
lower than those that initially failed to prevent rejection. The 
tolerance was complete enough to allow the patients to go 
home to an unrestricted environment. Nine of the Brst 10 of 
these kidney recipients achieved prolonged graft survivaI,a° 
including 2 who bear the longest continuously functioning 
allografts in the world today (more than 35.5 years) and 
have been free from immunosuppression for 32 and 4 years, 
respectively.l06 
The practical as well as theoretical implications of these 
observations were recognized throughout the report: 
A state of relative immunologic non-reactivity seems to have been 
produced which has lasted for as long as 6 months .... It is not 
known whether this is due to a change in the antigenic properties 
of the homograft, or to an alteration in the specific [host] response 
to the stimulus of the grafted tissues. The apparent host-graft adap-
tation does, however, provide some hope for prolonged functional 
survival. ... It would seem probable that the [therapeutic] principles, 
as defined with the kidney, can eventually be applied to other organ 
homografts .... The prior knowledge that a rejection crisis is almost 
a certainty and that it usually can be managed by relatively conser-
vative means should serve as a deterrent to the excessive use of 
measures that may cause fatal bone marrow depression .... It is also 
conceivable that the avoidance of a primary host-graft reaction by 
these means [excessive immunosuppression] would prevent the 
adaptive process.3D 
At the time this bellwether series was compiled between 
the autumn of 1962 and April 1963, the only other active 
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clinical transplantation programs in the United States were 
in Richmond (directed by David Hume)107 and at the Peter 
Bent Brigham Hospital in Boston (directed by Joseph Murray 
and John Merrill).!05 The historically important program of 
Willard Goodwin at the University of California at Los 
Angeles (UCLA; see earlier89 ) had been closed because all the 
recipients died in less than 5 months. In Europe, TBI briefly 
remained the preferred treatment at the long-standing Paris 
centers of Jean Hamburger and Rene Kuss, while Michael 
Woodruff of Edinburgh had begun testing azathioprine. 108 
The results in the Colorado series, and more importantly 
an exact description of the strategy that had been used to 
induce variable degrees of incomplete tolerance (Table 79.4), 
created a surge of new activity. Within 12 months, new 
kidney transplant centers proliferated in North America and 
Europe. Most of these second-generation programs remain in 
operation today. 
The observations in the original kidney recipients were 
promptly confirmed. However, the proposed explanation 
for these successes (i.e., graft alteration plus loss of specific 
immunological responsivenessj3° was controversial and 
remained so for the next three decades (see the section, 
/I Allograft Acceptance Versus Acquired Tolerance"). Except 
for reports from the University of Colorado, the term toler-
ance was studiously avoided from 1964 onward in referring 
to the long-surviving dogs and human kidney recipients that 
were evident by the end of 1963. 
The article most often quoted as contravening tolerance 
was that of Murray et al.,I02 despite the fact that, as the 
authors took pains to make clear, the evidence in their report 
was inconclusive and involved only two canine experiments 
of a potentially crucial nature. The two long-surviving dogs 
had been given renal homo grafts 9 and 18 months previously 
and had been treated for most of these periods with one of 
the purine analogues. Renal function was deteriorating at the 
time contralateral kidneys from the original donors were 
transplanted. The second organs were rejected after 23 and 3 
days, respectively, as would be expected. 
In commending Murray's 1964 report and conclusions, 
Medawar wrote lO9: 
There is, however, something special about renal homografts, as 
IMichael] Woodruff's appraisal in this volume makes very clear. A 
synoptic survey of more than 1000 renal homografts in dogs carried 
out by Murray and his colleagues I Murray, Ross Sheil, Moseley, 
Knight, McGavic &. Dammin, 1964)102 has shown that foreign 
kidneys do sometimes become acceptable to their hosts for a reason 
other· than acquired tolerance in the technical sense .... There has 
been an adaptation of some kind ... a possibility Woodruff has long 
urged us not to overlookllO,1Il though there is no reason to believe it 
an antigenic adaptation. 
!ABLE 79.4. Empircal Therapeutic Dogma of Immunosuppression. 
~edients of strategy 
Baseline therapy 
Secondary adjustments of prednisone dose, or 
antllymphoid agentsb 
~-to-case trial land potential error) of weaning 
Baseline agents 
Azathioprine" 
Cyclosporine 
Tacrolirnus 
'AlaIne ar With prophylactic prednisone. Equivalent results were obtained with 
eye aphosphamide instead of azathioprinel73,174 
bIni 
tially used for prophylactic "induction."ls6 
Medawar continued109: 
One possible explanation is the progressive and perhaps very exten-
sive replacement of the vascular endothelium of the graft by endo-
thelium of host origin, a process that might occur insidiously and 
imperceptibly during a homograft reaction weakened by immuno-
suppressive drugs .... Another possibility, raised by R.Y. Calne 
(though not mentioned by him in his contribution to this volume) 
is the laying down of a protective coat of host antibody on the 
endothelial inner surface of the graft ... an explanation which 
would classify the phenomenon under the general heading of 
"enhancement. " 
These disclaimers notwithstanding, the commonality of the 
rejection barrier for different organs was self-evident. So was 
the likelihood that the means of inducing acceptance of one 
organ could be used for all the others. l12 There also was evi-
dence from earlier experiments that a liver allograft could 
protect other donor tissues and orga.ns. It had been noted in 
1962 that intestine and pancreas had very little histopatho-
logical evidence of rejection in untreated canine recipients 
if they were components of multivisceral allografts that 
also included the liver.1I3 The observations were confirmed 
30 years later in a rat version of the same multivisceral 
procedures.1I4,lIs . 
Most convincingly at an experimental level, it was shown 
in 1964 that orthotopic canine liver allografts could induce 
and maintain their own acceptance far more frequently and 
permanently than renal allografts, even with a treatment 
course of azathioprine as short as 4 months.1l6,1l7 Soon there-
after, spontaneous engraftment was demonstrated after liver 
transplantation in untreated outbred pigs,118-122 many of which 
passed through self-resolving rejection crises.121,123,124 
Thus, it already was clear by 1964-1965 that the liver is 
the most tolerogenic organ. In the late 1960s and early 1970s, 
Calne, Zimmerman, and Karnada formally proved that the 
liver tolerization extended to other donor tissues transplanted 
at the same time or later, first in untreated outbred pigsl2S and 
then without immunosuppression in selected rat strain com-
binations. 126-128 Although they were important, the experi-
mental studies with hepatic allografts only affirmed the 
conclusion reached with the 1962-1963 experience in clinical 
renal transplantation, suggesting that all organs were capable 
of inducing tolerance. Just as with liver allografts, the self-
induction of donor-specific tolerance by heart and kidney 
allografts without the aid of immunosuppression was later 
demonstrated by Corry et al,l29 and Russell and coworkers l30 
in selected mouse strain combinations. 
The key mechanism of kidney-induced allograft accep-
tance was suggested as early as 1964 to be clonal exhaus-
tion. l3l This concept was developedl32 more fully for liver 
allografts in the illustration and caption reproduced in Figure 
79.2, published in 1969. Induction of the activated clone by 
alloantigen was depicted via host macrophages rather than 
by antigen-presenting dendritic cells, which would not be 
describedl33 until 1973. In the text accompanying the figure, 
it was pointed out that exhaustion and deletion of an antigen-
specific clone had been postulated by Schwartz and Dameshek 
as early as 1959 to be the mechanism of the tolerance to 
heterologous protein induced in rabbits with the aid of 
6-mercaptopurine.90 In addition, Simonsen had suggested 
in 1960 that clonal exhaustion induced by allogeneic 
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FIGURE 79.2. Hypothesis published in 1969 of allograft acceptance 
by clonal exhaustion. Antigen presentation was depicted via the 
macrophages rather than by the dendritic cells (which had not yet 
been described). A gap in this hypothesis was the failure to stipulate 
the location of the immune activation. (From Starzl,132 by pennission 
of W.E. Saunders Co.) 
splenocytes could lead to the acquisition of tolerance in adult 
animals in the absence of immunosuppression.134 
The error of making a semantic distinction between toler-
ance and graft acceptance was understandable. The picture 
that had emerged from the remarkable accomplishments with 
clinical kidney transplantation between January 1959 and 
the spring of 1963 was not a product of new insight in 
immunology. Instead, successful organ transplantation was 
an intellectually troubling and inexplicable violation of the 
immunological rules of the time. The revolution in immunol-
ogy that had already began, and would continue for the next 
third of a century, did little to change this view. 
The Burnet antibody hypothesis of clonal selection (see 
earlierl3 ) was validated and extended to cellular immunity by 
the late 1950s,135-137 but this had minimal influence on the 
clinical development of transplantation; neither did many 
other key advances in immunology that were either contem-
poraneous with or came after the rise of organ transplanta-
tion. The role of the thymus in the ontology of the immune 
system and in the postnatal immune function of rodents was 
Tissue twater Electrolytes Lymphocytes Serum proteins 
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~ / \ ' 
• '" 'r:--; --1~ i----y8 
Top view Cross section 
FIGURE 79.3. Schematic representation of diffusion chamber used 
in studies by Algire,l44 from which he concluded that lymphocytes 
were the cellular agents of allograft rejection. (From Starzl and Butz,l46 
by pennission of Surgical Clinics of North America.) 
discovered in 1961 (by Jacques Millerl38, 139). However, in 
humans thymectomy did not significantly alter either the 
early or late course of kidney transplant recipients. 140,141 Lym-
phocytes were not formally assigned a function until19631by 
James GowansI42,143), although workers in transplantation 
were aware several years earlier that these mononuclear leu-
kocytes were the cellular agents of allograft rejection l 44- 146 
(Fig. 79.3). By the time the distinction was clearly established 
between T and B lymphocytes, transplantation was an estab-
lished specialty of clinical medicine. 
Thus, the ascension of organ transplantation came as a 
surprise to most immunologists. Even as the clinical advances 
had begun to unfold, Bumet137 had written in the New England 
Journal of Medicine that, "Much thought has been given to 
ways by which tissues or organs not genetically and anti-
genically identical with the patient might be made to survive 
and function in the alien environment. On the whole, the 
present outlook is highly unfavorable to success." Pessimism 
also was deeply ingrained in conventional practitioners of 
medicine. Well into the 1960s, editorials were published in 
major clinical journals that questioned both the inherent fea-
sibility and the ethical basis of transplantation procedures. 147 
As a consequence, transplantation acquired a renegade image, 
a burden soon compounded by difficulties in extending its 
reach to the replacement of vital organs other than the 
kidney. 
One dilemma, as it was perceived at the time, is shown 
in Figure 79.4. 148 It was feared that chronic drug immunosup-
pression powerful enough to prevent organ allograft rejection 
would render the recipient hopelessly vulnerable to indige-
nous and environmental pathogens. Reports of infectious 
disease complications in the early Colorado recipientsl49 and 
elsewhere gave warning that dire consequences might, in 
time, be in store for all recipients. It also was suspected 
that immune surveillance to tumors would be eroded, a pos-
sibility that was verified but by 1958 was shown to be 
manageable. 150-152 
Autopsy studies in failed clinical cases revealed a typical 
pattern. Infections for which specific antibiotics were avail-
able could be largely controlled. However, opportunistic 
Host defense 
Bacteria IMMUNOSUPPRESSION 
(peak at rejection crisis) Bacteria 
FIGURE 79.4. The original legend for this figure was "Possible mech-
anisms of simultaneous loss of host reactivity to specific strains of 
endogenous bacteria, as well as to the alien renal tissue./I [From Starzl 
et al./ 48 by permission of Surgery (St. Louis).] 
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microorganisms of nonnally low pathogenicity were over-
represented and appeared at autopsy to be the main cause of 
death.153 Of these infections, cytomegalovirus (CMV) was the 
most common and lethal. The presence of Pneumocystis 
carinil as a coinfection with CMV154 premonstrated the lethal 
role of this combination of infectious agents in the acquired 
immunodeficiency syndrome (AIDS) epidemic in the non-
transplant population that lay two decades ahead. 
The Maturation of Transplantation 
Although it was entirely empirical, the practical framework 
required for the maturation of clinical transplantation was 
essentially complete by the end of 1963. Without knowing 
either the nature of the normal immune response or the way 
in which it had been subverted, surgeons had leamed how 
to reliably redirect the immune response with the aid of 
immunosuppression. Surgical (see opening section) and pres-
ervation techniques (see later) had been developed for trans-
plantation of all the organs; these are used currently with only 
minor modifications. Yet, the field of organ transplantation 
stalled and now entered a phase that was euphemistically 
termed consolidation. The reason was the failure to find 
improved means of exploiting the principles for control of 
rejection that had been established with azathioprine and 
prednisone (see Table 79.4). 
Improved Immunosuppression 
ANTILYMPHOID STRATEGIES 
Between 1963 and 1979, the only significant advance in clin-
ical immunosuppression was the introduction in 1966 of het-
erologous antilymphocyte globulin (ALG).155,156 This step was 
a logical extension of Gowan's demonstration of the immu-
nosuppressive effects of lymphoid depletion with thoracic 
duct drainage (TDD) in rats. 142,143 In fact, Woodruff and Ander-
son showed that TDD and antilymphocyte serum (ALS) had 
addi:ive effects. 1s7 
Franksson and Blomstrand used TDD clinically in 1963 
to treat kidney recipients in Stockholm,ls8 an approach that 
resurfaced periodically during the next two decades (summa-
rized in Ref. 159). Conditioning with TDD before transplanta-
tion clearly reduced the frequency and vigor of kidney 
rejection, but 30 days of pretreatment were required in 
humans/59.l60 compared to the 5 days in Gowan's rats. 142,143 
However, the inconvenience, complexity, and expense of 
TDD precluded its wide use. 160 For the same reasons, total 
lymphoid irradiation (TLI), 161 which also was an effective 
:neans of lymphoid depletion but with the disadvantage that 
It Was not quickly reversible, did not have a lasting impact 
on clinical transplantation.162,163 
In contrast, ALG was a major turning point for two 
reasons. First, it was a critical factor in the emergence of 
extrarenal organ transplantation. Second, it was a proto-
type drug from which numerous variations evolved. The 
concept of mitigating cellular immunity with heterologous 
antibodies had been proposed by liya Metnikoff at the end 
of the 19th century164 and was revitalized by Inderbitzenl65 
and Waksman et al,l66 before Woodruff and Anderson/ 57 
Levey and Medawar,167 Monaco, Wood, and Russell,16B,169 and 
other surgeons recognized its potential role in clinical 
transplantation. 
In most of the animal investigations up to 1963, the anti-
lymphocyte antibodies were raised in rabbits, and in all cases 
the raw ALS was administered. In preparation for clinical 
trials, horse anti dog ALS was prepared, and the active moiety 
was refined from the gamma globulin. ISS After the product 
was shown to inhibit or reverse rejection in the canine kidney 
and liver transplant models,156 comparable horse antihuman 
ALG was produced from the serum of horses that had been 
immunized with leukocytes separated from human lymphoid 
organs (lymph nodes, spleen, thymus).lss 
The first clinical trial of ALG began in 1966. Daily injec-
tions were given to kidney recipients for 1 to 4 postoperative 
weeks as a short-term adjunct to continuous azathioprine 
and prednisone. 156 After encouraging results were obtained 
in the kidney trial, liver transplantation was resumed, with 
long survival of several patients. The successful liver replace-
ments19 in the summer of 1967 expanded the horizon of trans-
plantation to the other vital extrarenal organs. Within the 
succeeding 27 months, heart/O,21 lung/2 and pancreas trans-
plantation23 also were accomplished using variations of the 
treatment shown in Table 79.4. As had happened with kidney 
centers in 1963, a wild proliferation of extrarenal (particularly 
heart) programs followed. However, almost all of them closed 
within the next 2 years because of an overwhelming failure 
rate. 
Polyclonal ALG was never used in more than about 15% 
of kidney transplant cases reported to registries up to the early 
1980s, in part because it was in no sense a standardized drug 
like azathioprine and prednisone. Although the use by Najar-
ian and Simmons170 of known numbers of cultured human 
lymphoblasts for accurately timed horse immunization 
improved the predictability of the ALG potency, batch-to-
batch variations in potency remained problematic. II Antibody 
therapy" came of age with production of monoclonal antibod-
ies made feasible by the hybridoma technology of Kohler and 
Milstein. l7l The first-generation murine monoclonal antibody 
muromonab CD3 (Orthoclone OKT3) was directed at the 
CD3 antigen present on all T lymphocytes. 172 Subsequent 
antibody preparations, which include less-immunogenic 
humanized "hybrids," have been directed at discrete targets 
such as T-cell subsets, adhesion molecules, and T-cell or 
interleukin 2 receptors. However, when these agents are used, 
the "induction" strategy has been essentially the same as 
with the original crude ALG. 
CYCLOPHOSPHAMIDE 
Although the experience in this middle era, defined by the 
first triple-drug regimen, demonstrated the feasibility of 
transplanting the vital extrarenal organs, it also indicated that 
further progress would require better baseline immunosup-
pression. Substitution of the alkylating agent cyclophospha-
mide for azathioprine was such an effort. ln The characteristic 
cycle of immunological confrontation and resolution leading 
to graft acceptance was no different with this drug than with 
azathioprine-based therapy. However, when the results with 
kidney and liver transplantation were almost identical to 
those using azathioprine but at a higher price of complica-
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tions, the trials were discontinued. 174 Although cyclophos-
phamide thereby became a footnote in the history of organ 
transplantation, it continued to playa role in bone marrow 
transplantation. 
CYCLOSPORINE 
Another decade would pass before the greater potency of 
cyclosporine would make transplantation of the liver and 
other cadaveric organs (including the kidney) a reliable service. 
Cyclosporine, an extract from the fungi Cylindrocarpon 
lucidum and Trichoderma polysporum, was discovered by 
Dreyfuss et al. llS and characterized biochemically by Ruegger 
et al. 176 and Petcher et al. 177 It was shown to be immunosup-
pressive by Borel et al. 17a-ISO with multiple test systems, 
including skin allotransplantation in mice, rats, and guinea 
pigs. 
The drug depressed humoral and cellular immunity and 
had a preferential and quickly reversible action against T 
lymphocytes. Unlike azathioprine and cyclophosphamide, 
these effects were not accompanied by bone marrow depres-
sion or other prohibitive organ toxicity. The ability of cyclo-
sporine to prevent or delay rejection of hearts, kidneys, livers, 
or pancreases was promptly shown in rats, rabbits, dogs, and 
pigs by Kostakis,181 Calne,I82-184 and Green185 and their asso-
ciates. There was no hint in these preclinical studies that 
nephrotoxicity would be the dose-limiting factor in human 
trials. 
The toxicity profile of cyclosporine became evident in 
Calne's initial evaluationl86,187 of cyclosporine in human 
recipients of 32 kidneys, 2 pancreases, and 2 livers, reported 
in 1978-1979. The ability of the drug to prevent rejection, 
alone or in combination with myelotoxic drugs, exceeded 
anything previously seen. However, the requisite overdosage 
caused multiple serious side effects: nephrotoxicity, neuro-
toxicity, diabetogenicity, a 10% incidence of B-cell lym-
phoma, and cosmetic changes (gingival hyperplasia, facial 
brutalization, and hirsutism). 
When cyclosporine in lower doses was combined with 
prednisone in the treatment algorithm shown in Table 79.4, 
the prognosis of cadaver kidney recipients was improved/88 
and transplantation of the liver,189 heart,190,191 and lungs192 was 
brought to the level of a practical clinical service. Recapitulat-
ing the aborted avalanche of 1967, many new extrarenal pro-
grams appeared, joining the five extant liver centers (Denver 
[from 1963t Cambridge [1968J, Hannover [1972t Paris [1974L 
and Groningen [1977]) and the single remaining heart program 
(Stanford [from 1968]). This time, most of the programs 
flourished. 
TACROLIMUS 
Cyclosporine was the unchallenged baseline immunosuppres-
sant for all varieties of transplantation until it was shown in 
1989 that intractably rejecting liver allografts could be regu-
larly rescued by replacing cyclosporine with tacrolimus,193 an 
extract of Streptomyces tsukubaensis discovered by Kino 
et al. 194 Tacrolimus was tested initially in a rat cardiac 
transplant model by Ochiai et al. 195 and soon thereafter by 
Murase et al. in rats 196,197 and by Todo et al. in dogs198.199 and 
subhuman primates. 199,200 
TABLE 79.5. Nonimmunological Profile. 
FK506 CyA 
N ephrotoxici ty ++a ++ 
Neurotoxicity + + 
Diabetogenicity + + 
Growth effects 
-Hirsutism 0 +++ 
Gingival hyperplasia 0 ++ 
Facial brutalization 0 + 
Hepatotrophic effects ++++ +++ 
Gynecomastia 0 + 
Other metabolic effects 
Cholesterol increase Ob ++ 
Uric acid increase +1 ++ 
All effects dose-related; ++++, worst. 
'Less hypertension. 
bIn rats, Van Thiel has shown an increase in cholesterol synthesis and serum 
concentration. 
Source: From S tarzl et a1. 210 
In addition to numerous confirmatory reports of its ability 
to rescue about 75 % of intractably rejecting human liver 
allografts/01 tacrolimus could salvage an equal proportion of 
rejecting hearts, kidneys, and other organs.202 In virtually all 
such cases, a switch back to cyclosporine was never made. 
Consequently, clinical trials using tacrolimus primarily were 
begun.202-204 
By early 1990, more than 150 liver, kidney, heart, and 
heart-lung recipients had been treated from the time of trans-
plantation with immunosuppression based on tacrolimus (FK 
506) rather than cyclosporine (CyA).2°S It was learned from 
this experience that the three major side effects of the drug 
(nephrotoxicity, neurotoxicity, and diabetogenicity) were 
comparable to cyclosporine. Hypertension and hyperlipid-
emia were less than in historical cyclosporine controls. The 
cosmetic effects of cyclosporine were not seen (Table 79.5). 
The effective use of both cyclosporine and tacrolimus 
required the same pattern recognition and therapeutic 
response that have guided organ transplantation since its 
inception (see Table 79.4). The dose ceilings of the four widely 
used baseline immunosuppressants were imposed by toxicity: 
myelotoxicity for azathioprine and cyclophosphamide and 
the more complex side effects shown in Table 79.5 for cyclo-
sporine and tacrolimus. The dose floors were revealed by the 
breakthrough of rejection. Because none of the four drugs 
could be used alone, they had to be incorporated into II cock-
tails" in which the requisite doses of the individual drug 
constituents were determined on a case-by-case basis by trial 
and error. Dose-maneuverable prednisone has remained a 
constant for 36 years, but steroid dependence declined with 
the more potent baseline agents. 
The lead organ for azathioprine was the kidney. The 
developmental responsibility for cyclosporine was shared 
by the kidney and liver, while the liver bore the principal 
burden for tacrolimus. 193,201,203,205-209 However, progress with 
one kind of organ allograft inevitably meant progress for 
all. Thus, survival of each kind of organ graft rose in the 
same three distinct leaps between 1962 and 1998 (Fig. 79.5). 
With tacrolimus, the intestine was no longer a IIforbidden" 
organ.21()..'lI2 
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FIGURE 79.5. The three eras of orthotopic liver transplantation at 
the universities of Colorado (1963-19801 and Pittsburgh (1981-1993), 
defined by azathioprine (AZAI, cyclosporine (CYA), and FK 506 
(tacrolirnusl"based (TAC) immunosuppression. The same stepwise 
improvement was seen with all organs. Top: Patient survival. Bottom: 
Graft survival. These results were about 10% lower than patient 
survival in both the cyclosporine (1980-19891 and tacrolirnus eras 
(1989-1993) because of effective retransplantation, an option that did 
not exist previously. 
The Ripple Effect 
Organ Procurement and Preservation 
The sudden arrival of clinical kidney transplantation in 1962-
1963 was so unexpected that little collateral research or other 
formal preparation had been made to preserve organs. 
Although kidneys were successfully transplanted in the 
pioneer identical twin cases despite protracted periods of 
warm ischemia, the maturation of clinical transplantation 
could not proceed without effective organ conservation. This 
Was accomplished at first with total body hypothermia of 
living volunteer kidney donors,213 using methods developed 
by cardiac surgeons for open-heart operations.214 In the exper-
imental laboratory, Lillehei et aP9 simply immersed the 
excised intestine in iced saline before its autotransplantation, 
a method also used by Shumway in developing experimental 
and clinical heart and heart-lung transplantation.44-46 Thus, 
the principle of hypothermia was understood at an early time, 
although it was not efficiently applied. 
The first major innovation in hypothermia was in the 
laboratory, when canine liver allografts were cooled by infu" 
sian of chilled fluids into the vascular bed of hepatic allografts 
Via the portal vein.42 Before this time, survival of dogs after 
liver transplantation was almost never obtained, while after-
Ward SUccess became routine. In a logical extension to clinical 
kidney transplantation, the practice was introduced in 1963 
of infusing chilled lactated Ringer's or low molecular weight 
dextran solutions into the renal artery of kidney grafts imme-
diately after their removaP15 
Today, intravascular cooling is the first step in the pres-
ervation of all whole-organ grafts. For cadaver donors, this is 
most often done in situ by some variant of the technique 
described by Marchioro et aP16 (Fig. 79.6). This method for 
the continuous hypothermic perfusion of cadaveric livers and 
kidneys was used clinically long before the acceptance of 
brain death. Ackerman and Snell217 and Merkel, Jonasson, and 
Bergan21B popularized the simpler core cooling of cadavers 
with cold electrolyte solutions infused into the distal aorta. 
ORGAN PROCUREMENT 
Until 1981, transplantation of the extrarenal organs was an 
unusual event. By late 1981, however, it had become obvious 
that liver and thoracic organ transplant procedures were going 
to be widely used. A method of multiple-organ procurement 
was required by which the kidneys, liver, heart, and lungs 
or various combinations of these organs could be removed 
without jeopardizing any of the individual organs. "Flexible 
techniques" were developed219,220 that were quickly adopted 
worldwide. With the methods, all organs to be transplanted 
are cooled in situ, rapidly removed in a bloodless field, and 
dissected on a back table. The sharing of organs from a 
common donor by recipient teams from widely separated 
centers became routine by the mid-1980s. 
Ex Vrvo PERFUSION 
Extension of the safe period after initial cooling has followed 
one of two prototype strategies, developed either with kidneys 
/~ 
( A 
B 
FIGURE 79.6. Technique of extracorporeal perfusion with a heart-
lung machine described by Marchioro et al.216 Catheters are inserted 
via the femoral vessels into the aorta and vena cava as soon as pos-
sible after death. The extracorporeal circuit is primed with a glucose 
or electrolyte solution to which procaine and heparin are added. The 
cadaver is thus anticoagulated with the first surge of the pump. 
Temperature control is provided by the heat exchanger. Cross-clamp-
ing the thoracic aorta limits perfusion to the lower part of the body. 
(From Starzl,215 by permission of W.B. Saunders Co.) 
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or livers and applied secondarily to other organs. One 
approach, which was extensively evaluated by Alexis Carrel 
and the aviator Charles A. Lindbergh, was to simulate normal 
physiological conditions with ex vivo perfusion techniques.221 
This concept was modified by Ackerman and Barnard,122 who 
provided the isolated organs with a continuous low-flow renal 
arterial circulation using a perfusate primed with blood and 
oxygenated within a hyperbaric oxygen chamber. This tech-
nique also pern1itted good preservation of hepatic allografts 
for as long as a day.123 However, the complexity of the method 
precluded its general use. 
The elimination of the hemoglobin and hyperbaric 
chamber components by Belzer et aP24 resulted in satisfac-
tory kidney preservation for as long as 2 to 3 days. The asan-
guinous perfusion technique eventually was abandoned in 
most kidney transplant centers when it was learned that the 
quality of 2-day preservation was not better than with the 
simpler "slush" methods (see following). Nevertheless, it 
is expected that refinement of perfusion technology will 
someday permit true organ banking. 
SLUSH PRESERVATION 
With the so-called static methods, fluids of differing osmotic, 
oncotic, and electrolyte composition are infused into the 
allograft before placing it in a refrigerated container.22S,226 The 
solution described by Collins, Bravo-Shugarman, and Tera-
saki225 (which resembles intracellular electrolyte concentra-
tions) or modifications of it were used for almost two decades. 
Renal allograft preservation was feasible for 1 to 2 days, long 
enough to allow tissue matching and sharing of organs over 
a wide geographic area. Experiments with hepatic allografts 
by Benichou et a1,227 using the Collins-Terasaki solution and 
by Wall et al.228 with the plasma-like Schalm solution led 
directly to liver sharing between cities, but with a time 
limitation of only 6 to 8 h. 
The introduction for liver transplantation of the Univer-
sity of Wisconsin (UW) solution by Belzer, Jamieson, and 
Kalayoglu,229,230 was the first major development in static 
preservation since the Collins-Terasaki solutionYl The supe-
riority of the UW solution for preservation of the kidney and 
other organs was promptly demonstrated in experimental 
models and confirmed in clinical trialS.237,-237 The UW preser-
vation doubled or tripled the time of safe preservation of the 
various allografts, making national and international sharing 
of most organs an economical and practical objective. 
The Life Sciences 
While occupying its own unique niche, transplantation has 
drawn from and in turn enriched all the other basic and 
clinical scientific disciplines. Aside from changing the phi-
losophy by which organ-defined specialties of surgery and 
medicine are practiced, transplantation grew parallel with, 
and contributed in a major way to, advances in immunology, 
pharmacology, oncology (e.g., the role of tumor immune sur-
veillanceI52,238), infectious disease, intensive care, and anes-
thesiology. Study of each of the different kinds of allografts 
has yielded an organ-specific harvest of special information. 
Examples include a better understanding of diabetes mellitus 
with pancreas transplantation and of the effects of denerva-
tion on cardiopulmonary function with heart and lung trans-
plantation. 
The liver became the key organ in unmasking the 
secrets of acquired tolerance because of its large content of 
immunocompetent leukocytes (see earlier and the section 
JJ Allograft Acceptance Versus Acquired Tolerance"). In addi~ 
tion, the functional complexity of the liver as well as its 
metabolic interactions with other abdominal viscera have 
made hepatic transplantation a JJmother lode" for physiolog-
ical studies.239 
In the course of deterrninirlg the optimal revascularization 
of auxiliary livers transplanted to ectopic sites or to the 
normallocation/2,240,24! it was found that endogenous insulin 
is a liver growth factor/42,243 the first such hepatotrophic 
factor to be identified. Using transplantation-derived models, 
a family of other molecules was delineated with insulin-
like hepatotrophic properties.244 Eventually, the gene was 
discovered that expresses one of these (augmenter of liver 
regeneration).245-247 The hepatotrophic factors, most of 
which are cytokines (e.g., hepatocyte growth factors [HGFsl), 
regulate liver size, structure, regeneration, and metabolic 
homeostasis. 
Studies of hepatotrophic physiology led directly or indi-
rectly to liver replacement for cure of more than two dozen 
hepatic-based inborn errors of metabolism,248 including famil-
ial hypercholesterolemia.249,250 The role of hepatic transplan-
tation in first suggesting, and then proving, that the liver 
governs cholesterol metabolism has been described else-
where. 238,249-25 I Elucidation of the cellular and molecular 
mechanisms was rewarded by bestowal of the 1985 Nobel 
Prize to Brown and Goldstein (see Table 79.2). 
Immunological Screening 
The importance of the genetically determined major histo-
compatibility complex (MHC) in determining the immune 
response to allografts was evident from investigations by 
George Snell in inbred mice,252 which in turn derived from 
the work of Peter Gorer (see JJthe seminal influence of Gorer 
and Snelll/253). However, the information was not clinically 
applicable. Thus, immunological screening of donors and 
recipients was not done during the volatile 1959-1963 devel· 
opmental period.! The possibility of tissue matching did not 
begin to emerge until the discovery in 1958 by Dausset of the 
first human leukocyte antigen (HLAj254 and the discovery in 
the same year by Van Rood et al.2S5 of antileukocyte antibod-
ies (soon shown to be HLA directed) in the sera of pregnant 
women. 
The report in 1964 by Terasaki and McClelland256 of the 
microcytotoxicity test, with which HLA antigens could be 
detected serologically in minute quantities of sera, was a 
critical development in moving forward with the classifica-
tion of the antigens. 
The Crossmatch Principle 
As it turned out, the greatest impact of pretransplant tissue 
matching has been the prevention of hyperacute rejection by 
observation of ABO compatibility guidelines and the routine 
use of the cytotoxicity crossmatch. 
r 
I 
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ABO COMPATIBILITY 
Hyperacute rejection was £Ist observed more than 30 years 
ago when ABO-mismatched renal allografts were transplanted 
into patients who had preformed antigraft ABO isoaggluti-
ninS.53,257 Aiter kidneys were lost on the operating table, arte-
rio grams of the infarcted organs showed nonfilling of the 
small vessels, correlating histopathologically with widespread 
thrombotic occlusion of the microvasculature. It was con-
cluded that high-affinity isoagglutinins in the recipient sera 
had bound to A or B antigens in the graft vessels and paren-
chymal cells. This finding was consistent with rapid changes 
in recipient isoagglutinin titers that followed organ revascu-
larization. The guidelines formulated from this experience53,2S7 
were designed to avoid such antibody confrontations (see 
Table 79.1). 
The ABO rules also apply to heart, liver, and other kinds 
of organ transplantation. As was originally observed in 1963 
with ABO-mismatched kidneys, however,53,2S7 not all organs 
placed in the hostile environment of antigraft isoagglutinins 
meet the same fate. In fact, the longest continuously func-
tioning renal allograft in the world106 is a B+ kidney donated 
to a then-38-year-old A+ male recipient by his younger sister 
on January 31, 1963. In addition, it was learned at an early 
time that the liver is more resistant to antibody attack than 
other organs.258 
In histocompatibility studies in which human volunteers 
were sensitized with purified A and B blood group antigens, 
causing variably increased titers of isoagglutinins, Rapaport 
et al. 2S9 showed accelerated or hyperacute (white graft) 
rejection of ABO-incompatible skin grafts transplanted to 
recipients with high titers. This result completed the circle 
of evidence indicating antigraft antibodies as the precipitating 
cause of hyperacute organ rejection. 
WITH NON-ABO ANTIBODIES 
In 1965, hyperacute rejection of a kidney by an ABO-compat-
ible recipient was reported for the £Ist time by Terasaki et 
al.260 Terasaki's observation that the serum of the recipient of 
a live donor kidney contained preformed antigraft lymphocy-
totoxic antibodies was promptly confumed in similar cases 
by Kissmeyer-Nielsen et al.261 and others.262,263 The evidence 
of a cause-and-ef£ect relationship in the single first case was 
so clear that Terasaki recommended and immediately intro-
duced his now universally applied lymphocytotoxic cross-
match test. 260,264 
. It has been shown in presensitized animals and humans 
that antibodies, clotting factors, and formed blood elements 
were rapidly cleared by the hyperacutely rejecting grafts.265,266 
Local fibrinolysis from the renal vein also was a consistent 
finding, and in exceptional cases, there were systemic coagu-
lopathies with disseminated intravascular coagulation 
IDIC). 267,268 The findings are comparable to those in the Arthus 
reaction, inverse anaphylaxis, generalized Shwartzman reac-
tion, and other models of innate immunity.263,267,268 
Non-HLA antibodies such as antivascular endothelial cell 
antibodies also have been associated with hyperacute or 
accelerated rejection.269,270 The vulnerability of extrarenal 
organs to this kind of rejection was ultimately demonstrated 
experimentally271-273 and clinically. Although the liver was 
t~e most antibody-resistant,258 it also was placed at increased 
nsk by the presensitized state.274 Hyperacute rejection also 
has been documented in a small number of human organ 
recipients in the absence of detectable antibodies. 263,275 
Tissue Matching 
Historically, it was predicted tissue matching would have to 
be perfected if long-term engraftment of tissues and organs 
was to succeed with any degree of reliability and predictabil-
ity. The prophecy was immediately fulfilled with bone 
marrow transplantation, in which anything less than a perfect 
or near-perfect match between the donor and recipient 
resulted in GVHD or rejection of the graftKOE~-O9 When similar 
expectations were not met in studies by Paul Terasaki in 
kidney transplant recipients, the results initially were treated 
as a scientific scandaP76,277 When he later was proved to have 
been correct, Terasaki emerged as the father of HLA matching 
and as an enduring symbol of integrity. 
Terasaki's investigations began with a retrospective study 
of the influence of HLA matching on the quality of outcome 
of patients bearing long-surviving kidney allografts,278 fol-
lowed by a prospective trial in live donor kidney recipients 
treated with azathioprine and prednisone, with or without 
adjunct ALG.279 Consistent with the results in the classic skin 
graft investigations in nonimmunosuppressed healthy volun-
teers by Rapaport and Dausset,280-282 HLA-matched allografts 
had the best survival and function, least dependence on main-
tenance prednisone, and fewest histopathological abnormali-
ties in routine 2-year postoperative biopsies,283 Unexpectedly, 
however, a cumulative adverse effect of mismatching in the 
kidney recipients could not be identified. 
The equally imprecise prognostic discrimination of HLA 
matching in cadaver kidney transplant cases also was first 
recognized by Terasaki (with Mickey et aI,284) and has been 
evident in analyses up to the present time. With the large 
sample sizes in United Network for Organ Sharing lUNaS) 
and European databases, virtually every comparison of the 
different levels of mismatching showed statistical signifi-
cance. However, the absence of a large or consistent matching 
effect unless there is a perfect or near-perfect match has 
always been the same, In a recent study of more than 30,000 
UNOS patients for whom optimal matches had been sought 
prospectively, approximately 85 % of the cases were in the 
two- to five-HLA-mismatch spectrum in which i-year 
survival was clustered within 3%. Subsequent half-life 
projections thereafter were in the narrow spread of 9 to 11 
years. 285 
Terasaki's conclusions nearly three decades ago breathed 
life into the still-struggling fields of liver, heart, and lung 
transplantation. It was a relief to know that the selection of 
donors with random tissue matching would not result in an 
intolerable penalty. A quarter of a century passed before it 
could be explained why HLA matching was critical for bone 
marrow, but not organ, transplantation (see next section). 
Allograft Acceptance Versus 
Acquired Tolerance 
During the Festschrift at Harvard honoring Paul Russell's 
retirement in late November 1990, Norman Shumway told 
me and Leslie Brent about his text on Thoracic Transplanta-
tion for which he wanted two chapters: one explaining the 
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Immune 
Reaction 
Time after Transplantation 
FIGURE 79.7. Contemporaneous host-versus-graft (HVG) and graft-
versus-host (GVH) reactions in the two-way paradigm of transplanta-
tion immunology. Following the initial interaction, the maintenance 
of nonreactivity of each leukocyte population to the other is seen as 
a predominantly low-grade stimulatory state that may wax and 
wane. 
classic immunolOgical tolerance exemplified by bone marrow 
transplantation and the other defining the presumably differ-
ent mechanisms of whole-organ allograft acceptance. On 
learning that I thought the two were the same in principle, 
Shumway assigned me to the task of defending this 
opinion.286 
Evidence was obtained first from investigation of long-
surviving human liver, kidney, and other organ recipi-
ents31,32,287-289 and then from detailed confirmatory animal 
studies.29O-293 The observation that all 30 patients tested had 
low-level (rnicro-) chimerism conformed perfectly with the 
hypothesis being tested that allograft acceptance involved 
not only chimerism but also a bidirectional immune reaction 
(Fig. 79.7). The relative strengths of the opposing immune 
reactions following organ transplantation were simply the 
reverse of those following bone marrow transplantation to the 
cytoablated recipient (summarized in Refs. 33 and 106). With 
this paradigm, it has been possible to view the historical 
milestones of clinical organ as well as bone marrow trans-
plantation in a coherent way.34 
Historically, an organ allograft had been envisioned as 
defenseless and vulnerable to immunological attack in pro-
portion to its histoincompatibility (Fig. 79.8, top left). The 
same dogma in reverse (Le., the host was the defenseless 
target) was the conventional view of bone marrow transplan-
tation (Fig. 79.8, top right). Only two pioneer workers raised 
objections to the definition of transplantation immunology 
in terms of a unidirectional immune reaction. In 1960-1961, 
Simonsenl34 and then Michie, Woodruff, and Zeiss294 postu-
lated that the two populations of immune cells in neonatally 
tolerant mice managed to coexist in a stable state qy be-
coming mutually nonreactive while retaining the ability to 
function collaboratively (i.e., in a joint immune response to 
infection). 
Although this heretical suggestion resembled the concept 
summarized in Figures 79.7 through 79.11, in 1962 the Simon-
sen-Woodruff hypothesis was recanted,295 ostensibly because 
no experimental support could be found for it. More impor-
tant, however, it had been advanced in a nonreceptive climate 
in which "group think" had already turned in a different 
direction. For the next 30 years, transplantation immunity 
and tolerance were conceived as products of unidirectional 
immune reactions of the kind that could be studied in 
vitro by one-way mixed-lymphocyte culture techniques 
described by Bain, Vas, and Lowenstein296 and Bach and 
Hirschhorn.297 
After chimerism was discovered in 1992-1993 in organ 
recipients,31-33 it was recognized that the interaction of the 
coexisting donor and recipient leukocyte populations was the 
common factor that underlay both the" acceptance" induced 
by whole-organ allografts (Fig. 79.8, bottom left) and the 
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FIGURE 79.8. Top panels. One-way paradigm 
in which transplantation is conceived as 
involving a unidirectional immune reaction: 
left, host-versus-graft (HVG) with whole 
organs; right, graft-versus-host (GVH) with 
bone marrow or other lymphopoietic trans-
plants. Bottom panels. Two-way paradigm in 
which transplantation is seen as a bidirec· 
tional and mutually canceling immune reac· 
tion that is (left) predominantly HVG with 
whole-organ grafts and (right) predominantly 
GVH with bone marrow grafts. 
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FIGURE 79.9. Continuum of chimerism from observations of Ray 
Owen in freemartin cattle to the discovery in 1992 of micro-
chimerism in organ recipients. . 
tolerance induced with bone marrow (Fig. 79.8, bottom right). 
This context closed the 3D-year intellectual gap between the 
fields of organ and bone marrow transplantation. Organ-asso-
ciated chimerism then could be identified in a continuum of 
classic tolerance models/,1l,161,298-300 beginning with the origi-
nal observations by Owen in freemartin cattle (Fig. 79.9). 
Organ Engraftment 
The immunocompetent donor leukocytes in organ transplan-
tation are highly immunogenic multilineage "passenger leu-
kocytes" of bone marrow origin (including stem and dendritic 
cells) that migrate preferentially to host lymphoid organs and 
are replaced in the graft by host cells. The result is widespread 
antigen-specific immune activation of the coexisting donor 
and recipient cells, each by the other, which proceeds in suc-
cessful cases to variable reciprocal clonal exhaustion and then 
deletion (Fig. 79.7). 
Engraftment under clinical circumstances requires an 
umbrella of immunosuppression to prevent one cell popula-
tion from destroying the other, but in some experimental 
models it occurs spontaneously (e.g., after pig liver transplan-
tation and in many rodent models). The "nullification" of the 
two arms explains the poor prognostic value of HLA matching 
for organ versus bone marrow transplantation (Table 79.6) and 
the low incidence of GVHD following the engraftment in 
FIGURE 79.11. Variable outcomes 
after infection with widely dissem-
lUated noncytopathic viruses lor 
other microorganisms) and analo-
gIes (in the text below the horizon-
tal axes) to organ and bone marrow 
transplantation. Horizontal axis, 
tlrlJ.e; vertical axis, viral load (v, 
Solid line) and host immune 
response (1R, dashed line). 
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FIGURE 79.10. The four events that occur in close temporal approx-
imation when there is successful organ engraftment. Top, double 
acute clonal exhaustion (1, 2) and subsequent maintenance clonal 
exhaustion 13) plus Ibottom) loss of organ immunogenicity caused by 
depletion of the graft's passenger leukocytes 14). 
noncytoablated recipients of immunologically active organs, 
such as the intestine and liver. 
In addition to inducing clonal activation and exhaustion 
by trafficking to host lymphoid organs, donor leukocytes that 
survive the initial destructive immune reaction migrate sec-
ondarily to nonlymphoid areas, where they do not generate 
an immune response ("immune indifference"). From· here 
they may "leak" periodically to the host lymphoid organs and 
maintain clonal exhaustion. With clonal exhaustion/deletion 
and immune indifference in combination, both of which are 
regulated by the migration and localization of the antigen,33 
the four interrelated events shown schematically in Figure 
79.10 must occur close together to have organ engraftment: 
double acute clonal exhaustion; maintenance clonal exhaus-
tion, which frequently waxes and wanes; and loss of graft 
immunogenicity as the organ is depleted of its passenger 
leukocytes. 
Bone Marrow Tolerance 
Pretransplant cytoablation renders the recipient susceptible 
to immune attack by donor immune cells (i.e., GVHD), 
control of which frequently becomes the principal objective 
of immunosuppression rather than the prevention of rejec-
tion (see Table 79.6). Because complete destruction of host 
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TABLE 79.6. Differences Between Conventional Bone Marrow and 
Organ Transplantation. 
Bone marrow Organ 
Yes -Recipient cytoablationa - No 
Critical -MHC compatibility- Not critical 
GVHD -Principal complication- Rejection 
Common -Drug-free state- Rare 
Tolerance ~ Term for success..." f( AcceptanceJlb 
'Note: All differences derive from this therapeutic step, which in effect estab· 
IIshes an unopposed GVH reaction in the bone marrow recipient whose coun· 
tervailing lmmune reaction is eliminated. 
bOr "operational tolerance." 
leukocytes is not possible with conventional doses of cytoab-
lation,301 the remaining cells will stimulate an alloresponse 
by mature or maturing donor T cells. Nevertheless, under 
immunosuppressive treatment, a weak host-versus-graft reac-
tion mounted by these few recipient cells and a parallel graft-
versus-host reaction mounted by the donor bone marrow cells 
may eventually result in reciprocal tolerance by deletion. 
These processes represent a mirror image of the events after 
organ transplantation (see Fig. 79.8, bottom right). 
Relation to Infectious Disease 
N ONCYTOPATHIC MICROORGANISMS 
Early workers in transplantation302,303 recognized the resem-
blance of allograft rejection to the response against infections 
associated with delayed hypersensitivity, exemplifl.ed by 
tuberculosis. With the demonstration in 1973 of the MHC-
restricted mechanisms of adaptive infectious immunity by 
Doherty and Zinkernagel/0<h307 it became obvious that 
allograft rejection must be the physiological equivalent of the 
response to this kind of infection. Microorganisms that gener-
ate such an adaptive immune response are generally intra-
cellular and have no or low cytopathic qualities.30B 
Although MHC-restricted host cytolytic T lymphocytes 
recognize only infected cells, elimination of all the infected 
ce~ls could disable or even kill the host. Consequently, mech-
arusms have evolved that can temper or terminate the immune 
response, allowing both host and pathogen to survive.30B,309 
These are the same two mechanisms that allow survival of 
allografts (i.e., clonal exhaustion/deletion and immune indif-
ference),33 both of which are governed by antigen migration 
:md localization.33,30B,309 However, unlike the complex dual 
Immune response of transplantation, infectious immunity is 
essentially a host-versus-pathogen reaction. 
The analogies between transplantation and an infection 
with disseminated noncytopathic microorganisms can be 
exemplmed by the common hepatitis viruses as shown in 
Figure 79.1L33,30B,309 The pathogen (antigen) lo;d may rapidly 
llcrease dunng the so-called latent period, but then be dra-
matically and efficiently controlled by antigen-specmc effec-
tor T cells, which then subside (left panel). The transplantation 
analogues are acute irreversible rejection (or intractable 
GVHD). Alternatively, a continuously high antigen load with 
an antigen-specific immunological collapse (second panel) is 
eqUlvalent to unqualified acceptance of an allograft. 
Between these two extremes, the persistence of both the 
infectious agent and a strong immune response result in 
serious immunopathology [e.g., chronic active hepatitis with 
a B or C virus infection) comparable to chronic rejection after 
liver transplantation (third panel) OI, uncommonly, GVHD. 
The conditions in the cytoablated bone marrow recipient 
mimic those of an infection by microorganisms [e.g., rabies 
and wart viruses) that avoid immune activation by not migrat-
mg through or to host lymphoid organs (right panel).33 
Because immunity and tolerance to alloantigens follow 
the same rules as the response to noncytopathic microorgan-
isms/3 it is not possible with current transplantation prac-
tices to induce tolerance to allografts on the one hand without 
risking unwanted tolerance to pathogens on the other. In 
this context, the historical anxiety depicted in Figure 79.4 
was correct. 
CYTOPATHIC MICROORGANISMS 
There is no MHC-restricted safety valve for cytopathic micro-
organisms, which are typically extracellular and generate the 
full resources of the innate as well as the adaptive immune 
system.30B,309 An uncontrollable innate immune response 
involving the effectors shown in Table 79.7 is provoked by 
discordant xenografts expressing the Ga1-a-Gal epitope an 
epitope that also is found on numerous cytopathic bact~riaI 
protozoa, and viruses. 
The clinical use of such discordant animal donors will 
require changing the xenogeneic epitope to one that mimics 
a noncytopathic profile or else elimination of the epitope.310 
Although chimpanzees and baboons do not express the Gal 
antigen, the clinical xenografts transplanted in 1963 from 
these subhuman primate donors50,51 ultimately were damaged 
by an uncontrollable innate immune reaction, dominated by 
complement activation. Similar innate immune mechanisms 
were recognized in the 1960s to be responsible for the hyper-
acute destruction of ABO-incompatible allografts or allografts 
transplanted to presensitized recipients (see earliey263-268). 
Self-Nonself-Discrimination 
Survival in a hostile environment requires the ability to 
mount a protective immune response while avoiding a reac-
tion of the immune system against self. Transplantation has 
succeeded because it has not lethally eroded this capability, 
which depends ultimately on the governance of immuno-
logical responsiveness or unresponsiveness by migration 
and localization of antigen.33 Because the fetus possesses 
very early T-cell immune function/ 1l-313 the ontogeny of 
self-nonself-discrimination during fetal development can be 
explained by the same mechanisms as acquired tolerance in 
TABLE 79.7. Effectors Involved in Response to Cytopathic 
Parasites and Discordant Xenografts. 
The first line of defense 
Interferons 
Macrophages 
Gamma/delta T cells 
Natural killer (NK) cells 
B cells 
Nonspecific or less-specific effectors 
Complement 
Early interleukins 
Phagocytes 
I j 
I 
I 
i 
I 
L 
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later life. Autoimmune diseases then reflect unacceptable 
postnatal perturbations of the prenatally established local-
ization of self-antigens in nonlymphoid versus lymphoid 
compartments.33 
Conclusion 
The lesson described in this chapter has been learned many 
times before: All knowledge can be traced to its roots and 
ultimately to a seed. For clinical transplantation, the histori-
cal beginning was Medawar's recognition that rejection is an 
immune reaction. Only two primary roots sprang from this 
seed. One was the demonstration by Billingham, Brent, and 
Medawar in 1953 that tolerance could be acquired by produc-
ing stem cell-driven hematolymphopoietic chimerism5; this 
concept ultimately led to bone marrow transplantation in 
humans. 
The other root was the demonstration during 1962-:-1963 
that kidney allografts could consistently self-induce tolerance 
with the aid of immunosuppression30; all further develop-
ments in organ transplantation were derivative from this dis-
covery. The assumption reached by consensus in the early 
1960s that the two roots reflected different immune mecha-
nisms led to inadequate explanations of organ allograft accep-
tance and clouded the meaning of successful bone marrow 
transplantation. 
The false assumption, which promptly became dogma, 
saddled succeeding generations of scientists and clinicians 
with a context that precluded the synthesis of a clarifying 
central principle of immunology that could be applied to all 
transplant, much less non transplant, circumstances. After it 
was discovered in 1992 that organ recipients had persistent 
microchimerism, it was possible to see the essential com-
monality of organ and bone marrow transplantation, to relate 
observations after these procedures to the immune response 
to infectious diseases and neoplasms, and to explain the 
genesis of self-nons elf-discrimination. 
Epilogue 
This chapter was originally prepared between August 1997 
and August 1998. The immunologic paradigm that had 
emerged by then3l-34,106,287-293 was finalized in two collabora-
tive reviews with RolfZinkemagel (Nobel Laureate, 1996).314,315 
It proved difficult to explain the new concept to persons 
whose career development (or legacy) during the preceding 
third of a century depended on not understanding it. The 
bitter pill that had to be swallowed was the reality that 
almost all of the clinical and experimental observations in 
transplantation immunology, and particularly those involved 
With organ engraftment, had been inserted from 1962 onward 
into an invalid intellectual framework. The consequence of 
the error was an epistemologic collapse, that is, a failure to 
understand.316 As for the new paradigm, no modifications of 
the chapter written in 1997-1998 have been necessary. More-
Over, the fresh insight into immunoregulation has been sys-
tematically exploited for therapeutic purposes under numerous 
transplant_ and nontransplant-related circumstances.3l7-319 
Thus, both the old and new history of transplantation is a 
Work in progress. 
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